Payment overview · 2025
General Payments
$538.82
23 reported records · 10 companies
Healthcare provider profile · identity verified
Jacob Yankowitz, DO
Allopathic & Osteopathic Physicians|Family Medicine · HILLSBORO, MO · NPI 1427619196
Verified facts
What the public records show
CMS Open Payments records show Jacob Yankowitz, DO received $538.82 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.63 | 37.8% | 10 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $116.33 | 21.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $57.41 | 10.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.25 | 6.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.98 | 6.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.62 | 5.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.24 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.13 | 2.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.83 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.40 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $500.28 | 22 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $116.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.47 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.47 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $57.41 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 355 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 96 |
| Lisinopril | Lisinopril | 245 | 79 |
| Alprazolam | Alprazolam | 200 | 49 |
| Omeprazole | Omeprazole | 158 | 48 |
| Gabapentin | Gabapentin | 152 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 128 | 103 |
| Trazodone Hcl | Trazodone Hcl | 117 | 28 |
| Losartan Potassium | Losartan Potassium | 115 | 37 |
| Mounjaro | Tirzepatide | 115 | 28 |
| Metformin Hcl | Metformin Hcl | 112 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 30 |
| Prednisone | Prednisone | 108 | 73 |
| Azithromycin | Azithromycin | 107 | 75 |
| Lorazepam | Lorazepam | 105 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 31 |
| Simvastatin | Simvastatin | 95 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 21 |
| Tramadol Hcl | Tramadol Hcl | 84 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 13 |
| Famotidine | Famotidine | 66 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 30 |
| Sertraline Hcl | Sertraline Hcl | 61 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 24 |
| Furosemide | Furosemide | 58 | 21 |
| Montelukast Sodium | Montelukast Sodium | 58 | 17 |
| Baclofen | Baclofen | 55 | 13 |
| Bupropion Xl | Bupropion Hcl | 53 | 16 |
| Meloxicam | Meloxicam | 53 | 20 |
| Naproxen | Naproxen | 50 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Allopurinol | Allopurinol | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 18 |
| Buspirone Hcl | Buspirone Hcl | 41 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Pregabalin | Pregabalin | 40 | 12 |
| Carvedilol | Carvedilol | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Ozempic | Semaglutide | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 12 |
| Diazepam | Diazepam | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 29 |
| Benzonatate | Benzonatate | 31 | 16 |
| Fluconazole | Fluconazole | 31 | 18 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Eliquis | Apixaban | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Spironolactone | Spironolactone | 24 | 11 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.82 · 23 records | Amgen Inc. | AIRSUPRA, FARXIGA, GLASSIA, INGREZZA, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error